Bart Vanhaesebroeck Selected Research

Phosphatidylinositol 3-Kinases (PI 3 Kinase)

10/2019	p110δ PI3-Kinase Inhibition Perturbs APP and TNFα Trafficking, Reduces Plaque Burden, Dampens Neuroinflammation, and Prevents Cognitive Decline in an Alzheimer's Disease Mouse Model.
1/2019	Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner.
11/2017	Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism.
12/2014	Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α.
9/2013	Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis.
4/2013	Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism.
4/2008	Activation of phosphoinositide 3-kinase by the NBS1 DNA repair protein through a novel activation motif.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bart Vanhaesebroeck Research Topics

Disease

46	Neoplasms (Cancer) 01/2022 - 04/2003
10	Inflammation (Inflammations) 01/2020 - 04/2005
7	Insulin Resistance 01/2021 - 11/2012
7	Thrombosis (Thrombus) 01/2018 - 01/2010
5	Breast Neoplasms (Breast Cancer) 01/2022 - 04/2003
5	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 01/2006
4	Infections 09/2021 - 08/2005
4	Obesity 01/2021 - 11/2009
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2013 - 08/2005
3	Leukemia 05/2014 - 08/2012
3	Hypersensitivity (Allergy) 05/2014 - 02/2008
2	Fatty Liver 01/2021 - 12/2015
2	Atrophy 01/2021 - 01/2019
2	Neuroinflammatory Diseases 10/2019 - 03/2014
2	Cardiotoxicity 01/2019 - 03/2015
2	Lymphopenia (Lymphocytopenia) 01/2017 - 10/2007
2	Glucose Intolerance 01/2016 - 05/2006
2	Carcinogenesis 10/2014 - 04/2008
2	Arthritis (Polyarthritis) 08/2014 - 04/2011
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Olfactory Esthesioneuroblastoma (Esthesioneuroblastoma) 01/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022
1	Weight Loss (Weight Reduction) 01/2021
1	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 01/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Epstein-Barr Virus Infections 01/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 10/2020
1	Neoplasm Metastasis (Metastasis) 10/2020
1	Ciliopathies 01/2020
1	Hypothyroidism 01/2020
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020
1	Primary Immunodeficiency Diseases 01/2020
1	Alzheimer Disease (Alzheimer's Disease) 10/2019
1	Cognitive Dysfunction 10/2019
1	Right Ventricular Dysfunction 01/2019
1	Pulmonary Arterial Hypertension 01/2019
1	Ventricular Fibrillation 01/2019
1	Heart Failure 12/2018
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 12/2018
1	Heart Diseases (Heart Disease) 12/2018

Drug/Important Bio-Agent (IBA)

27	Phosphatidylinositols (Phosphatidylinositol)IBA 10/2021 - 04/2003
22	Protein Isoforms (Isoforms)IBA 10/2021 - 04/2003
14	Phosphotransferases (Kinase)IBA 01/2022 - 04/2008
13	Pharmaceutical PreparationsIBA 12/2019 - 01/2006
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2005
7	EnzymesIBA 10/2020 - 10/2008
7	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 10/2019 - 04/2008
6	Insulin (Novolin)FDA Link 01/2021 - 03/2009
5	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 11/2012
5	idelalisibIBA 01/2020 - 03/2014
5	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019 - 05/2006
4	AlpelisibIBA 10/2021 - 01/2019
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 10/2020
3	somatostatin receptor 2IBA 01/2022 - 01/2021
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2021 - 01/2018
3	LigandsIBA 10/2020 - 03/2009
3	CollagenIBA 01/2018 - 08/2014
3	CytokinesIBA 03/2014 - 02/2007
2	AntibodiesIBA 10/2020 - 06/2012
2	LeptinIBA 01/2016 - 11/2009
2	LipidsIBA 10/2014 - 01/2010
2	phosphatidylinositol 3,4,5-triphosphateIBA 10/2014 - 02/2012
2	IntegrinsIBA 08/2014 - 10/2011
2	Biological ProductsIBA 04/2013 - 03/2013
2	AutoantibodiesIBA 06/2012 - 04/2011
2	Oncogene Proteins (Oncogene Protein)IBA 01/2012 - 01/2010
2	Immunoglobulin E (IgE)IBA 02/2008 - 10/2007
2	ChemokinesIBA 02/2007 - 04/2005
1	N- (1- (7- fluoro- 2- (pyridin- 2- yl)quinolin- 3- yl)ethyl)- 9H- purin- 6- amineIBA 01/2022
1	Androgen Receptors (Androgen Receptor)IBA 01/2022
1	2- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA 01/2022
1	inavolisibIBA 01/2022
1	metabotropic glutamate receptor type 1IBA 01/2022
1	Cell Surface ReceptorsIBA 09/2021
1	Sunitinib (Sutent)FDA Link 10/2020
1	AntigensIBA 10/2020
1	T Cell Transcription Factor 1IBA 10/2020
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2020
1	Angiogenesis InhibitorsIBA 10/2020
1	Phenobarbital (Luminal)FDA Link 01/2020
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2020
1	copanlisibIBA 01/2020
1	duvelisibIBA 01/2020
1	IC 87114IBA 01/2020
1	Amyloid (Amyloid Fibrils)IBA 10/2019
1	Peptides (Polypeptides)IBA 10/2019
1	AnthracyclinesIBA 01/2019
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019
1	p38 Mitogen-Activated Protein KinasesIBA 01/2019
1	Trastuzumab (Herceptin)FDA Link 01/2019
1	human ERBB2 proteinIBA 01/2019
1	GelsolinIBA 12/2018
1	Immune Checkpoint InhibitorsIBA 01/2018

Therapy/Procedure

12	Therapeutics 01/2022 - 06/2006
3	Immunotherapy 10/2021 - 10/2016
1	Drug Therapy (Chemotherapy) 09/2021
1	Radiotherapy 09/2021
1	Immunomodulation 10/2020
1	Oncolytic Virotherapy 01/2020